AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|
10.9 C
New York
Monday, October 19, 2026

Tag: cancer

Medicovestor, Inc. and Sanyou Biopharmaceuticals Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates

Medicovestor and Sanyou team up to develop first-in-class chemoimmunotherapy ADCs, combining AI antibody tech with novel dual-targeting platforms.

MD Anderson and HealthEx Announce Collaboration to Develop New Platform to Give Patients Direct Control of Data Access

The University of Texas MD Anderson Cancer Center and HealthEx are developing an AI platform to give patients more control in how their data is used.

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology")...

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well...

Portage Biotech and Compedica Stock-for-Stock Exchange

Portage Biotech and Compedica Stock-for-Stock Exchange

Nord Anglia Education Awards Over $155,000 in 2025 ‘Social Impact Grants’ to Student-Led Global Projects Advancing UN SDGs

Student-led projects driving innovation in AI, healthcare, sustainability, and inclusive education across Nord Anglia's global schools LONDON, June 9, 2025 /PRNewswire/ -- Leading international schools organisation...

CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform

Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program

Tech Legend Bill Atkinson Logs Off at 74

Back in November 1983, I had my first run-in with Bill Atkinson while reporting on the soon-to-launch Macintosh. You know, back when the personal...

Over 4,400 Riders Embark on Ride to Conquer Cancer, Canada’s Largest Athletic Fundraiser, Raising Over $20.61 Million for Life-Saving Research

Riders Begin 2-Day, 200+ KM Journey in Support of The Princess Margaret for a World Free From the Fear of Cancer TORONTO, June 7, 2025...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. – URGN

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ: URGN). Such investors...

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating...

URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd.

Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug Candidate

UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA’s Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens Berman

URGN Investors with Losses Encouraged to Contact Hagens Berman
URGN Investors with Losses Encouraged to Contact Hagens Berman

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer